Shifting Toward Sustainable Reimbursement Models in South Africa’s Healthcare Sector

By João L. Carapinha

November 4, 2025

Escaping Fee-for-Service: Pathways to Sustainable Reimbursement Models The Council for Medical Schemes (CMS) Annual Report 2024/25 undersc...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks

By HEOR Staff Writer

November 3, 2025

Antidepressant side effects vary widely among medications, impacting heart health, weight, and metabolism in distinct ways. If you're wondering how these drugs affect your body, a recent systematic review and network meta-analysis in The Lancet shows key differences. For ex...
China Medical Research Challenges: Pushing Boundaries Amid Ethical and Quality Concerns
China's medical research challenges are starkly evident in Kamran Abbasi's editorial in The BMJ, which portrays the country's medical research landscape as a dual-edged sword. It highlights rapid modernization, massive investments in infrastructure and cohort studies, and i...
Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 2024/25

By João L. Carapinha

October 31, 2025

The CMS Annual Report 2024/25 highlights significant medical schemes affordability challenges in South Africa, where relevant healthcare expenditure per beneficiary surged by 8.70% year-on-year, far outpacing both contribution growth and general inflation. Solvency ratios have declined for three ...
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for s...
Aligning Medical Schemes with National Health Insurance South Africa
The National Health Insurance initiative in South Africa is advancing toward universal health coverage, and the recent CMS Annual Report 2024/25 highlighted the regulator's pivotal role in supporting this framework by integ...
Search By Category

Latest

Shifting Toward Sustainable Reimbursement Models in South Africa’s Healthcare Sector

By João L. Carapinha

November 4, 2025

Escaping Fee-for-Service: Pathways to Sustainable Reimbursement Models The Council for Medical Schemes (CMS) Annual Report 2024/25 undersc...

Latest

Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks

By HEOR Staff Writer

November 3, 2025

Antidepressant side effects vary widely among medications, impacting heart health, weight, and metabolism in distinct ways. If you're wondering how these drugs affect your body, a recent systematic review and network meta-analysis in The Lancet shows key differences. For ex...

Latest

China Medical Research Challenges: Pushing Boundaries Amid Ethical and Quality Concerns
China's medical research challenges are starkly evident in Kamran Abbasi's editorial in The BMJ, which portrays the country's medical research landscape as a dual-edged sword. It highlights rapid modernization, massive investments in infrastructure and cohort studies, and i...

Latest

Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 2024/25

By João L. Carapinha

October 31, 2025

The CMS Annual Report 2024/25 highlights significant medical schemes affordability challenges in South Africa, where relevant healthcare expenditure per beneficiary surged by 8.70% year-on-year, far outpacing both contribution growth and general inflation. Solvency ratios have declined for three ...

Global Updates

Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks

By HEOR Staff Writer

November 3, 2025

Antidepressant side effects vary widely among medications, impacting heart health, weight, and metabolism in distinct ways. If you're wondering how these drugs affect your body, a recent systematic review and network meta-analysis in The Lancet shows key differences. For ex...

Global Updates

China Medical Research Challenges: Pushing Boundaries Amid Ethical and Quality Concerns
China's medical research challenges are starkly evident in Kamran Abbasi's editorial in The BMJ, which portrays the country's medical research landscape as a dual-edged sword. It highlights rapid modernization, massive investments in infrastructure and cohort studies, and i...

Global Updates

AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health

By João L. Carapinha

October 28, 2025

A BMJ article explores the potential for AI chatbot delusions to validate or induce delusional thinking. Emerging evidence shows that individuals with and without previous psychiatric histories have reported distressing delusions after extensive chatbot interactions. It remains uncertain if AI di...

Global Updates

Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...

Europe

Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks

By HEOR Staff Writer

November 3, 2025

Antidepressant side effects vary widely among medications, impacting heart health, weight, and metabolism in distinct ways. If you're wondering how these drugs affect your body, a recent systematic review and network meta-analysis in The Lancet shows key differences. For ex...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health

By João L. Carapinha

October 28, 2025

A BMJ article explores the potential for AI chatbot delusions to validate or induce delusional thinking. Emerging evidence shows that individuals with and without previous psychiatric histories have reported distressing delusions after extensive chatbot interactions. It remains uncertain if AI di...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics

By João L. Carapinha

October 27, 2025

Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...

North America

Obesity Health Economics: Forecasting Trends and Costs in the US

By HEOR Staff Writer

October 29, 2025

Obesity health economics Obesity health economics reveals a pressing public health crisis in the US, where rising prevalence drives massive costs and strains healthcare systems. If you're wondering how obesity impacts the economy, consider this: projections show annual expenses could su...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation

By João L. Carapinha

October 24, 2025

Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy

By João L. Carapinha

October 21, 2025

Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...

Sub-Saharan Africa

Shifting Toward Sustainable Reimbursement Models in South Africa’s Healthcare Sector

By João L. Carapinha

November 4, 2025

Escaping Fee-for-Service: Pathways to Sustainable Reimbursement Models The Council for Medical Schemes (CMS) Annual Report 2024/25 undersc...
Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 2024/25

By João L. Carapinha

October 31, 2025

The CMS Annual Report 2024/25 highlights significant medical schemes affordability challenges in South Africa, where relevant healthcare expenditure per beneficiary surged by 8.70% year-on-year, far outpacing both contribution growth and general inflation. Solvency ratios have declined for three ...
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for s...
Aligning Medical Schemes with National Health Insurance South Africa
The National Health Insurance initiative in South Africa is advancing toward universal health coverage, and the recent CMS Annual Report 2024/25 highlighted the regulator's pivotal role in supporting this framework by integ...